Elodie Vandenhaute, Project Director at HCS Pharma, leads a discussion group on utilising multi-cell type models to understand diseases, cells, and therapeutic mechanisms.

Find out about some of Oxford Global’s most highly anticipated presentations happening at our upcoming Vaccines Congress.

Upstream Bioprocess Development.

The panel at Immuno UK 2022 discuss the unique challenges that come with delivering immunotherapies to solid malignancies.

Unique Homebrew Kits give researchers the flexibility to develop custom Simoa assays.

Explore the future of single cell seeding.

The lack of predictive models is a highly limiting factor in the efficacy of projects designed to find new therapeutic targets. Cutting-edge organoid models may be the key to overcoming these challenges and could improve the prediction candidate drug molecules' clinical success.

Roche revealed that they will stop all Alzheimer’s trials after anti-amyloid beta antibody gantenerumab fails Phase III trials.

As an alternative avenue for addressing difficult-to-treat cancers, viral immunotherapies hold significant promise. CAN-2409 is well-tolerated in phase II clinical trials in patients with prostate cancer, and new applications may be on the horizon.

New data released from Amgen’s phase II study of olpasiran suggests that the drug could fill a niche in the cardiovascular market.

Mark Doherty, Senior Medical Manager at GSK, leads a Discussion Group on leveraging the mechanisms of action in therapeutic vaccine development.

The tumour microenvironment is a critical target to immuno-oncologists. Our discussion group brings together authorities in targeting the TME.